Comparative Role of Topical Betamethasone Valerate with Topical Calcipotriol in Mild and Moderate Plaque Type Psoriasis
Keywords:
Calcipotriol, betamethasone valerate, plaque psoriasis, psoriasis area severity index (PASI) parameterAbstract
Objective:
Comparative role of topical Betamethasone valerate (0.1%) and topical Calcipotriol (0.005%) inthe treatment of plaque psoriasis.
Materials and Methods:
This 12 weeks research project was conducted in the Department of Pharmacology and Therapeutics, BMSI, JPMC, Karachi. Total 80 psoriatic (mild and moderate) patients were included in the study and they were divided into two groups, A and B; 40 patients in each group. The patients of group A were treated by Betamethasone valerate (0.1%) and the patients of group B were treated by Calcipotriol (0.005%). To observe any significant changes, the PASI parameter was applied at the end of study period.
Results:
Psoriasis severity improvement was monitored by Psoriasis Area Severity Index (PASI). As comparedto day 0, the mean PASI score changes in both treated groups i.e group A (Betamethasone valerate) and groupB (Calcipotriol) was highly significant at day 90 but the changes in mean PASI score was more marked ingroup B. In mild psoriasis, Calcipotriol causes 71.61% improvement in PASI score whereas Betamethasonevalerate causes 63.2% improvement. In moderate psoriasis, Calcipotriol causes 69.21% improvement in PASI score whereas Betamethasone valerate causes 60.44% improvement.
Conclusion:
Topical Calcipotriol was more effective in improvement of mild and moderate plaque psoriasis as compared to Betamethasone valerate in local population.
Downloads
References
Bos JD, de Rie MA, Teunissen MB, Piskin G. Psoriasis deregulation of innate immunity. Br. J Dermatol 2005; 152:1098-1107.
Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician’s Global Assessment. J Am Acad Dermatol 2004; 51:563-9.
Traub M, Marshall K. Psoriasis Pathophysiology, Conventional and Alternative Approaches to Treatment. Altern Med Rev 2007; 12:319-30.
Griffiths CE, Camp RD, Barker JN. Psoriasis. In: Burns DA, Breathnach SM, Cox N, Griffiths CE, eds. Rook’s Textbook of Dermatology. 7th ed. Oxford: Blackwell 2005; 35:1-36.
Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 2001; 15:16-7.
Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K. Fitzpatrick's Dermatology in General Medicine. 6th ed. 2003.
"Psoriasis Update -Skin & Aging". Retrieved 2007-07- 28.
Dahri GM, Samdani AJ, Qazi N, Laghari MJ et al. To compare the role of calcipotriol alone versus combination with betamethasone in mild to moderate psoriasis. Sindh Univ Res J 2010; 42:69-72.
Ahmad GK, Choudhury AM, Khondker L, Khan MS. Comparative safety of topical calcipotriol (0.005%) versus topical corticosteroid (betamethasone 0.1%) in plaque type psoriasis. J Pak Assoc Dermatol 2013; 23:394-400.
Kragballe K, Austad A. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate twocompound product in the treatment of psoriasis. Br J Dermatol 2006; 6:1155-60.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 sana imran, Moosa Khan, Mohammad Sair, Sarwat Jahan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Articles published in the Journal of Dow University of Health Sciences are distributed under the terms of the Creative Commons Attribution Non-Commercial License https://creativecommons.org/ licenses/by-nc/4.0/. This license permits use, distribution and reproduction in any medium; provided the original work is properly cited and initial publication in this journal. 
